Welcome to our dedicated page for Senestech SEC filings (Ticker: SNES), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SenesTech, Inc. (NASDAQ: SNES) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. SenesTech is a biotechnology company focused on fertility control for managing rodent populations, and its filings offer detailed information on its operations, financing activities, and governance.
Key documents available through EDGAR and summarized with AI-powered insights include Form 10-K annual reports, which describe the business, risk factors, and strategy around products such as ContraPest® and the Evolve rodent birth control line, and Form 10-Q quarterly reports, which update investors on revenues, gross margins, operating expenses, and cash position. These periodic reports help readers understand how SenesTech’s fertility control products and multi-channel distribution efforts are reflected in its financial statements.
SenesTech also files numerous Form 8-K current reports documenting material events. Recent 8-K filings describe warrant inducement agreements and related financings, at-the-market offering prospectus supplements, the appointment and compensation of an interim chief operating officer, board changes, and the release of quarterly financial results. These filings provide structured detail on capital raises, equity-linked securities, and key management decisions.
Through this page, users can also review registration statements and prospectus supplements referenced in 8-Ks, which outline at-the-market equity programs and additional registered shares. Stock Titan’s tools surface new filings in real time and apply AI-generated summaries to highlight the main points of lengthy documents, helping investors quickly locate information on SenesTech’s financial condition, equity offerings, and significant corporate events without reading every page manually.
SenesTech (SNES) appointed Michael Edell as Interim Chief Operating Officer and outlined his compensation terms. The role is effective November 3, 2025, with an employment offer letter executed on November 7, 2025.
Edell will receive $30,000 per month and may earn bonuses of up to $25,000 for Q4 2025 and up to $30,000 for Q1 2026, subject to Board discretion. The agreement runs for six months on an at‑will basis. Either party may terminate with 60 days’ notice; the company can immediately relieve duties while continuing salary during the notice period. No additional compensation or benefits are provided unless authorized in writing, apart from requirements under California law, and Edell is restricted from competing during employment.
SenesTech (SNES) filed its Q3 2025 report, highlighting improved growth and liquidity. Revenue reached $690,000, up 43% year over year, driven largely by the Evolve product line, while ContraPest declined. Gross profit was $433,000 with a 62.8% margin in the quarter; for the first nine months, revenue was $1.8 million with a 64.2% gross margin. Net loss narrowed to $1.3 million for the quarter.
Management reports that prior substantial doubt about continuing as a going concern has been alleviated. During 2025, financing transactions generated $13.2 million in net proceeds, and cash, cash equivalents and short‑term investments totaled $10.2 million as of September 30, 2025, supporting at least the next 12 months. The company ended the period with 5,223,015 shares outstanding as of November 7, 2025. Operating cash use improved versus last year, and higher interest income reflected larger average balances.
Evolve Rat and Evolve Mouse now comprise the majority of sales across e‑commerce, professional, and retail channels. Operating expenses were stable year over year as cost containment offset higher legal and franchise fees. An at‑the‑market program added $2.7 million year to date, and warrant exercises added $10.5 million, bolstering liquidity while the company works toward higher‑margin growth.
SenesTech (SNES) announced its third‑quarter results for the period ended September 30, 2025. The company furnished a press release detailing these results as Exhibit 99.1 to a Form 8‑K under Item 2.02.
The disclosure is presented as furnished, not filed, under the Exchange Act. The company also stated it has no obligation to publicly update forward‑looking statements. The text referenced in the report may be available on www.senestech.com.
SenesTech (SNES) reported an insider ownership update via Form 3 for an officer serving as Interim Chief Operating Officer. The filing indicates no securities are beneficially owned (0) by the reporting person. The event date was 10/15/2025, and the form was filed by one reporting person.
The document was executed by Thomas C. Chesterman as attorney-in-fact.
SenesTech, Inc. (SNES) appointed Michael Edell as Interim Chief Operating Officer effective October 15, 2025. The company states there are no family relationships and no arrangements or understandings related to his election.
Edell will receive $30,000 per month and is eligible for a bonus at the Board’s discretion. Given the interim status, he will not receive standard benefits such as health insurance, retirement plans, paid time off, or other fringe benefits, and he will not be entitled to severance or other post‑termination compensation. He will be reimbursed for reasonable business expenses and will enter into the company’s standard indemnification agreement for officers.
SenesTech, Inc. filed an 8-K to report that it has filed a prospectus supplement registering an additional $7,580,675 of shares of its common stock under its existing at-the-market offering agreement with H.C. Wainwright & Co., LLC dated June 20, 2024. These shares may be issued from time to time through the sales agent under that agreement. The company states that, prior to this filing, it has already sold an aggregate of $3,048,894.72 of common stock through the same at-the-market program. A legal opinion from Greenberg Traurig, LLP regarding the validity of the newly registered shares is included as Exhibit 5.1, with its consent included as Exhibit 23.1.
SenesTech, Inc. has filed a new prospectus supplement allowing it to offer and sell up to $7,580,675 of common stock from time to time through H.C. Wainwright & Co. under an at-the-market Sales Agreement. This capacity reflects the $10,629,569.80 limit under General Instruction I.B.6 of Form S-3, after deducting $3,048,894.72 of securities sold in the prior 12 months. As of this supplement, SenesTech had 5,185,333 shares of common stock outstanding and an aggregate market value of non-affiliate holdings of $31,888,709.40, and sales remain subject to the one-third cap while that market value is below $75,000,000.
SenesTech, Inc. filed an S-3 shelf prospectus registering shares underlying warrants and common stock for resale by selling stockholders; its common stock trades on Nasdaq under the symbol SNES. The prospectus states proceeds will not be received by the company except for cash from any warrant exercises, which the company intends to use for general corporate purposes including R&D, capital expenditures, working capital and potential acquisitions though no commitments exist.
The filing highlights the company’s rodent fertility-control products (ContraPest and Evolve), asserts beliefs about product palatability and population impacts, and warns of continued operating losses, dependence on successful commercialization and regulatory approvals, and dilution risk from outstanding warrants and potential exercises subject to beneficial ownership limits. The prospectus discloses multiple selling stockholders and related warrant mechanics and includes exhibits, legal and accounting consents, indemnification provisions and customary plan-of-distribution methods.
SenesTech, Inc. (SNES) reporting: Lynn Yako filed an Initial Statement of Beneficial Ownership (Form 3) identifying her relationship to the issuer as a Director and reporting no securities beneficially owned. The event date listed is 07/05/2025 and the form bears a signature dated 08/02/2025. The filing includes an exhibit: a Limited Power of Attorney.
SenesTech, Inc. (a Delaware corporation with principal place in Surprise, Arizona) filed a Form D disclosing a Regulation D private offering of common stock warrants that raised an aggregate of $273,539. The filing reports the total amount sold as $273,539 with $0 remaining to be sold and indicates the offering relied on Rule 506(b). Five investors participated and the issuer states $0 of the gross proceeds were used to pay named executive officers.
The placement agent disclosed is H.C. Wainwright & Co., LLC, and the filing estimates sales commissions of $474,589. It also discloses placement agent warrants to purchase up to 72,944 shares at an exercise price of $5.4219 per share, plus accountable expenses and a management fee. The offering is not tied to a business combination and is not intended to last more than one year.